CN107098969B - 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用 - Google Patents

一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用 Download PDF

Info

Publication number
CN107098969B
CN107098969B CN201710507860.8A CN201710507860A CN107098969B CN 107098969 B CN107098969 B CN 107098969B CN 201710507860 A CN201710507860 A CN 201710507860A CN 107098969 B CN107098969 B CN 107098969B
Authority
CN
China
Prior art keywords
cell
car
antigen receptor
gly
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710507860.8A
Other languages
English (en)
Other versions
CN107098969A (zh
Inventor
张同存
顾潮江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Ruida Biotechnology Co. Ltd.
Original Assignee
Wuhan Ruida Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Ruida Biotechnology Co Ltd filed Critical Wuhan Ruida Biotechnology Co Ltd
Priority to CN201710507860.8A priority Critical patent/CN107098969B/zh
Priority to JP2019538366A priority patent/JP6890664B2/ja
Priority to EP17915822.5A priority patent/EP3511347A4/en
Priority to PCT/CN2017/099261 priority patent/WO2019000620A1/zh
Priority to US16/317,514 priority patent/US20190389940A1/en
Publication of CN107098969A publication Critical patent/CN107098969A/zh
Application granted granted Critical
Publication of CN107098969B publication Critical patent/CN107098969B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

本发明涉及感染性疾病免疫治疗技术领域,具体涉及一种治疗HIV感染的嵌合抗原受体(CAR)的重组基因构建及其应用。本发明提供了一种单链抗体ScFv,该单链抗体能够识别感染HIV病毒细胞表面的gp120,是通过串联针对感染HIV病毒细胞表面的gp120的抗体轻链、重链可变区而得到的;将该单链抗体制成嵌合型抗原受体(CAR),将CAR编码基因转入质粒载体,并将转入了CAR编码基因的慢病毒载体转导到CD8+T淋巴细胞,所得的CAR‑T淋巴细胞在体外实验和体内实验中均发现具有显著的抑制、杀灭HIV感染细胞的活性,能够作为活性成份制备抗HIV感染的药物,具有良好的应用前景。

Description

一种治疗HIV感染的嵌合抗原受体的重组基因构建及其应用
技术领域
本发明涉及感染性疾病免疫治疗技术领域,具体涉及一种治疗HIV感染的嵌合抗原受体的重组基因构建及其应用。
背景技术
艾滋病是由人类免疫缺陷病毒1型(Human Immunodeficiency Virus 1,HIV-1)感染引起的一种重大威胁人类生命安全的传染病,据世界卫生组织的最新统计,自发现到2014年底已造成3900多万人死亡,目前世界上艾滋病毒感染者仍有3700万。我国艾滋病毒感染者逐年增加,其总患病人数已突破百万。目前尚无有效疫苗且现有药物不能彻底治愈。
高效抗逆转录病毒治疗(HAART)是HIV/AIDS治疗史上的第一次革命,其极大的降低了HIV/AIDS的发病率和病死率,显著延长了患者寿命,甚至降低了HIV的传播。但也面临着很多挑战:1)患者必须终生服药,需付出昂贵的经济代价;2)严重的毒副作用;3)耐药毒株的出现;4)更为重要的是cART不能彻底清除病毒,主要是因为药物仅对复制中的病毒有效,而对HIV在感染早期建立的潜伏性病毒“储藏库”(reservoir)是无效的。一旦抗逆转录病毒治疗中断,病毒储藏库中的整合前病毒再度激活,几乎所有患者体内病毒血症会迅速反弹。
艾滋病毒在其传播和繁殖过程中的高变异性使得以往有效的艾滋病药物失效,因此出现了后来的“鸡尾酒疗法”,也就是联合多种抗病毒药物来进行高效抗逆转录病毒治疗,但是鸡尾酒疗法同样有着其局限性。综合目前国际上艾滋病研究的前沿和热点问题,研究者普遍认为HIV不能治愈的主要原因是HIV在感染极早期就在机体内建立起隐秘的病毒“储藏库”,即静息记忆的CD4+T淋巴细胞(Resting memory CD4+T)。
要找到治愈艾滋病的一个重大挑战,就是如何能够重新激活潜伏的HIV从而被机体的免疫系统自发识别和清除(shock and kill)。同时,研究发现,即使在接受cART治疗的感染者体内,也出现不可逆转的免疫损伤,特别是细胞毒性T细胞(CTL)的数量减少和功能缺陷,这表明通过抗逆转录病毒治疗重建的机体免疫系统将不能有效的清除那些被激活的细胞,需要通过联合增强机体HIV特异性免疫应答的方法来增强对HIV储藏库的清除效果。因此,对HIV潜伏性病毒“储藏库”的形成及激活策略和以重建机体免疫功能的探索都是迈向治愈HIV时代极有价值的研究方向。
近几年来,基于嵌合抗原受体(chimeric antigen receptor,CAR)肿瘤免疫治疗技术创造了杀伤肿瘤细胞的全新途径。由于其具有高亲和力和MHC(Majorhistocompatibility complex)非依赖性等优点,特别是由两个CD28及4-1BB、CD3ζ偶联形成的3代CAR可增强T细胞的杀瘤能力并延长了其在体内的存活时间,从而在白血病和淋巴瘤等肿瘤免疫治疗中取得了令人鼓舞的成效。其实早在1994年,Roberts等人尝试用CAR-T细胞治疗HIV感染,他们选取CD4序列作为单链抗体用于结合感染细胞表面的gp120,虽然具有部分杀感染细胞功能且经过多年的努力,但最终以失败而告终。其主要原因有以下几个方面:1.使用逆转录病毒载体转导效率较低,为了获得足够的可回输CAR-T细胞,过度的体外扩增导致回输后细胞死亡和CAR分子的丢失。2.CAR分子设计本身存在缺陷,其中CD4结构域可能引起转导的CTLs被HIV感染或者病毒感染细胞通过下调CD4分子的表达而逃脱CAR-T细胞的杀伤。
发明内容
本发明为了克服现有技术的上述不足,提供了一种新的能识别HIV病毒感染细胞表面gp120的单链抗体ScFv以及由此单链抗体制成的嵌合型抗原受体(CAR),称为N6-CAR分子。
本发明的另一目的是提供一种能表达上述N6-CAR的表达载体以及N6-CAR载体基因修饰的CD8+T淋巴细胞。
本发明的再一个目的是提供N6-CAR分子修饰的CD8+T淋巴细胞在制备抗HIV感染药物方面的用途。
为了实现上述目的,本发明是通过以下技术方案实现的:
提供了一种单链抗体ScFv,该单链抗体能够识别HIV病毒感染细胞表面的gp120,是通过串联针对HIV病毒感染细胞表面的gp120的抗体轻链、重链可变区而得,作为整个CAR分子的胞外结合结构域,其氨基酸序列如SEQ ID NO.2所示。
本发明也提供了编码上述单链抗体ScFv的编码基因,该基因的核苷酸序列如SEQID NO.1所示。
本发明还提供了一种治疗HIV感染的嵌合型抗原受体,该嵌合型抗原受体是通过N端到C端顺次拼接信号肽、本发明提供的单链抗体ScFv、CD8hinge、白细胞抗原分化群分子跨膜区CD28-TM及细胞内结构域ICD、4-1BB和白细胞抗原分化群3的ζ链CD3得到的,所得到的嵌合型抗原受体的氨基酸序列如SEQ ID NO.4所示。
本发明同时提供了编码上述的嵌合型抗原受体N6-CAR的编码基因,该基因的核苷酸序列如SEQ ID NO.3所示。
一种含有并能表达氨基酸序列为SEQ ID NO.4所示的嵌合型抗原受体N6-CAR的编码基因的表达载体,所述载体为以PTK881载体为骨架,将CMV启动子替换成EF1α启动子后改造成的PTK-EF1α-N6载体,其核苷酸序列如SEQ ID NO.5所示。
本发明提供了一种基因修饰的CD8+T淋巴细胞,是将PTK-EF1α-N6表达载体转染293T细胞所的慢病毒载体转导CD8+T淋巴细胞,从而获得能表达嵌合型抗原受体的基因工程化的T-淋巴细胞。N6-CAR改造的CD8+细胞对表达gp120细胞系的杀伤效果更加明显。
进一步地,所述的基因修饰的CD8+T淋巴细胞是由以下方法制备得到:从外周血分离PBMC后再用磁珠阳选获得CD8+T细胞,经anti-CD3/28磁珠(细胞与磁珠比例为1:3)刺激12小时后,加入重组有N6-CAR分子的慢病毒感染4小时后补液(MOI=5),从病毒感染后第三天开始,细胞计数并根据细胞状态和增殖情况补加培养基,细胞浓度调整至0.6x106/ml,并补充IL-2100U/mL,进一步扩增细胞直到满足回输的细胞数。
本发明同时提供了一种上述N6-CAR基因修饰的CD8+T淋巴细胞的用途,所述N6-CAR基因修饰的CD8+T淋巴细胞是应用于制备抗HIV感染的活细胞药物。
本发明的有益效果:(1)本发明中克服早期设计的缺陷,利用能与病毒蛋白Gp120高度特异性结合的广谱中和抗体作为ScFv,能与98%的HIV-1的病毒株结合,增加该CAR-T细胞的广谱性;(2)本发明中使用含有SIN(Self-inactivating)结构的PTK质粒来生产慢病毒载体增加安全性的同时,改造CAR分子细胞内为双刺激分子以其提高N6-CAR-T细胞的扩增和存活特性,增加临床有效性和安全性。(3)本发明中的能表达嵌合型抗原受体的基因修饰CD8+T淋巴细胞在体外实验和体内实验中均发现具有显著的抑制、杀灭HIV病毒的活性,能够作为活性成份制备抗HIV感染药物。
附图说明
图1为本发明构建的抗HIV感染的嵌合型抗原受体的结构示意图;
图2为本发明构建的PTK-EF1α-N6慢病毒载体结构示意图;
图3为本发明中N6-CAR在被转导的CD8+T淋巴细胞中的表达水平(A)及其刺激后功能性增殖能力(B)检测;
图4为本发明中N6-CAR转导的CD8+T淋巴细胞体外杀灭HIV感染细胞活性检测;
图5为共培养条件下本发明中N6-CAR转导的CD8+T淋巴细胞抑制病毒的活性检测;
图6为本发明中N6-CAR转导的CD8+T淋巴细胞杀灭人源化小鼠体内的HIV感染细胞活性检测。
具体实施方式
展示一下实例来具体说明本发明的某些实施例,且不应解释为限制本发明的范围。对本发明公开的内容可以同时从材料、方法和反应条件进行改进,所有这些改进,均应落入本发明的的精神和范围之内。
实施例1:
本发明提供了一种治疗HIV感染的嵌合抗原受体(CAR)重组基因及其构建方法,具体的拼接方法为:顺次拼接信号肽、能识别感染HIV病毒细胞表面的gp120单链抗体ScFv、CD8hinge、白细胞抗原分化群分子跨膜区CD28-TM+ICD、4-1BB和CD3(白细胞抗原分化群分子3)的ζ链,最后得到完整的能治疗HIV的嵌合型抗原受体(CAR)分子,其氨基酸序列见SEQID NO.4,其结构如图1所示;编码该嵌合型抗原受体(CAR)的基因的核苷酸序列如SEQ IDNO.3所示。
治疗HIV感染的嵌合型抗原受体来源的单链抗体ScFv的氨基酸序列如SEQ IDNO.2所示,该单链抗体ScFv是通过串联针对感染HIV病毒细胞表面gp120的抗体轻链、重链可变区而得,其编码基因的核苷酸序列如SEQ ID NO.1所示。
以SEQ ID NO.4所示的嵌合型抗原受体(CAR)分子详细介绍本发明CAR分子的结构设计。CAR分子的序列氮端是CAR来源的ScFv序列,可特异性识别感染HIV病毒细胞表面的gp120;CAR分子的序列碳端是以三代CAR结构为基础,包括CD8hinge、CD28TM+ICD、4-1BB和CD3ζ胞内结构域串联组成,通过CD28分子的跨膜结构域将ScFv和胞内信号分子相连。在上述的结构下各个片段能发挥如下的功能:信号肽可以将CAR分泌到胞外,CD28TM+ICD将本发明的CAR锚钉在细胞膜上;ScFv特异性识别识别感染HIV病毒细胞表面的gp120;CD3ζ为胞内信号激活序列,在ScFv结合抗原后CD3ζ激活信号,启动淋巴细胞的杀伤活性。
实施例2:CAR分子重组构建PTK-EF-1α-N6质粒表达载体
按照SEQ ID NO.4所示序列合成CAR,将全长CAR的编码基因通过基于无缝重组克隆技术插入目的表达载体(见图2)。经过多次试验,首选的质粒载体为以PTK881载体为骨架,将CMV启动子替换成EF1α启动子后改造成的PTK-EF1α-N6载体(其核苷酸序列如SEQ IDNO.5所示),最终获得了插入CAR基因并能表达CAR的重组质粒PTK-EF1α-N6载体,其核苷酸序列如SEQ ID NO.6所示。
病毒包装步骤如下:
1)取两个均装有16ml DMEM培养液的离心管,向其中一管加入960μg PEI,另一管加入320μg预混的PTK881载体质粒,漩涡震荡,室温平衡10分钟。
2)取一个10ml的移液管将混有PEI的培养基吹起来,将混有质粒的培养基一滴一滴地加入PEI中,室温温育30分钟。
3)取一个T175瓶,向其中加入3ml胎牛血清,将和PEI混合的PTK-EF1α-N6载体质粒加入其中,然后将多层细胞培养瓶中的培养基倒入到T175瓶,上下左右颠倒与质粒混匀,最后将T175瓶中的培养基倒回到多层细胞培养瓶中。37℃,5%CO2培养箱培养3天,收获上清。收集的上清4000rpm(3000g),30min离心去除293T细胞碎片。
4)将慢病毒液上清用0.22μm滤膜过滤后,分装到250ml的离心瓶中,于4℃,30000g离心2.5小时,离心后将离心瓶小心转移至生物安全柜,用真空泵去上清,留沉淀,加入T细胞培养基500μl/离心瓶,用枪将沉淀吹散混匀,即得到含N6-CAR分子的慢病毒载体,立即使用或分装后于-80℃保存。
实施例3:制备能表达嵌合型抗原受体的CD8+T细胞(CAR-T细胞)
步骤1:分离患者PBMC细胞
(1)采集人外周血样本60-80ml,边采集边摇晃使得外周血与抗凝剂充分混合;
(2)将外周血转入50ml离心管中,用DPBS缓冲液按1:1稀释外周血,混匀。将稀释好的血样缓慢加入室温的15ml人淋巴细胞分离液的离心管中。方法如下:用10ml移液管吸取血样,伸至分离液液面上方0.5cm处,血样自然滑落铺至分离液面上,然后轻轻加入血样,注意不要冲破液面;
(3)配平离心30min,慢升慢降;
(4)离心完成后,离心管出现明显分层由下至上:红细胞层,粒细胞层,Ficoll层、单个核细胞层和血浆层。吸取血浆层至距白膜层5mm左右处弃之。小心吸取红细胞层以上的所有液体至离心管中,PBS稀释,与细胞悬液体积比应大于1:3,混匀。
(5)离心(1600r/min)5min,PBS重悬细胞混匀,取少量细胞计数。
(6)离心300g(1200r/min)5min,上清液送检无菌检测。
步骤2:分选CD8+T细胞
(1)步骤1中的PBMC细胞,用30ml生理盐水重悬后取样计数(取样完后,补加至50ml混匀,500g、10min、18℃、升快、降快离心,去上清),计数后按每107/80μLbuffer混匀(如果上清没有去干净,建议不用加buffer),加入按每107/20μL CD8Microbeads重悬,4-8℃孵育15min。
(2)孵育完成后,使用按每107个1~2ml buffer洗细胞,500g、10min离心。
(3)用500μLbuffer重悬多达108个细胞(若细胞数目比较多,buffer使用的也会多)。
(4)将美天旎专用LS柱,置于磁力架上,使用3ml buffer冲洗LS柱后,将细胞重悬液加入到LS柱里,使之流尽。用3ml buffer洗LS柱三次,每次需要流尽。将LS柱离开磁力架,使用5ml buffer,加入到LS柱中,用活塞将标记后的细胞冲洗出来(可以冲洗两次,确保标记的细胞均可以冲洗出来)。
(5)CD8+T细胞冲洗出来后,用生理盐水重悬至30ml,取样计数,500g、10min、18℃离心,得细胞沉淀,即可用于培养。
步骤3:CD8+T细胞激活
(1)将步骤2中CD8+T细胞,计数,按密度为2x106/ml加入培养瓶中,混匀放入CO2培养箱培养2小时。
(2)取出培养瓶,轻摇,使沉降于底部的悬浮细胞浮起,移液管吸取培养基转入离心管中,少许培养基洗培养瓶将悬浮细胞全部收集,混匀计数。
(3)根据细胞计数调整细胞浓度,按1.2x106/ml的浓度接种培养瓶中(100~120mlin a T150,50~60ml in a T75,15~29ml in a T25),加CD3/CD28磁珠,按细胞与磁珠比例为1:3(加之前磁珠用培养基洗涤3次,去除保存液),加入IL-2100U/mL,混匀放入CO2培养箱培养,收集细胞。
步骤4:CD8+T细胞被转导N6-CAR分子制备CAR-T细胞
加入磁珠12小时后,取适量步骤3中生长状态良好的CD8+T细胞悬液,放入离心管中300g离心5分钟。弃去上清液,以1x106/ml细胞的比例加入嵌合型抗原受体(CAR)病毒载体,同时加入终浓度4μg/ml的Polybrene,混匀。将细胞悬液在37℃条件下小体积孵育。孵育4小时后补加适量T细胞完全培养基进行培养。细胞培养的第3天,细胞计数并根据细胞状态和增殖情况补加培养基,细胞浓度调整至0.6x106/ml,并补充IL-2100U/mL。细胞培养的第5天,细胞混匀转离心管中,在磁力架上去除磁珠,细胞计数并补加培养基,并补充IL-2100U/mL,细胞密度调整至0.6x106/ml继续培养。并利用流式检测SCFV的表达,同时,取部分CD8+T淋巴细胞经goat anti-human Fab antibody抗体刺激并连续传代,以确定anti-gp120CAR转导的CD8+T淋巴细胞自扩增能力,结果如图3所示。
结果表明,Anti-gp120CAR病毒转导细胞培养到五天后,有40%的CD8+T细胞表达CAR分子。当抗体goat anti-human Fab antibody特异性地与CD8+T细胞表达CAR分子结合后,能有效和剂量依赖地激活细胞的增殖,随着传代次数增加,CAR分子阳性细胞种群比例也逐渐升高。
实施例4:CAR-T细胞体外杀灭HIV感染细胞活性的检测
为了进一步检测N6-CAR的功能,我们将N6-CAR-T细胞与两株HIV-1感染的细胞系H9-NL4-3和H9-NDK分别进行混合培养,在U形底的96孔板中进行细胞杀伤实验。首先利用Calcein-AM标记HIV感染细胞系H9和阴性对照细胞,取100μl(含靶细胞数量104)于96孔板中,取100μl梯度稀释的CAR-T细胞加入相应的96孔板中,确保效靶比范围为5:1到10:1,每孔终体积为200μl。室温200g离心30分钟,37℃孵育2-3小时。离心取上清测定荧光并计算出裂解百分数并用于判断N6-CAR-T细胞对HIV感染细胞的细胞毒性,实验结果如图4所示。
结果显示,从5:1到10:1效靶比区间范围内,N6-CAR-T细胞以剂量依赖的方式显著杀伤两个毒株HIV感染的靶细胞系,而对对照靶细胞没有明显的杀伤效果,说明N6-CAR-T细胞杀伤靶细胞作用是HIV-gp120特异性的。
实施例5:共培养条件下CAR-T细胞体外抑制病毒复制活性的检测
为了进一步证明N6-CAR-T细胞在清除野生型HIV-1感染的原代CD4+T细胞方面的有效性,利用野生型HIV-1NL4-3-EGFP和NDK-EGEP两个毒株分别感染健康人血液样本中分离的CD4+T淋巴细胞,感染后3小时换液。感染后的第8天,该细胞与N6-CAR改造的同源CD8+T淋巴细胞以1:4的比例混合,在24孔板中进行细胞杀伤实验。靶细胞数量为106/孔,RMPI1640完全培养基体积为500μl/孔。48小时后,通过流式细胞术检测EGFP+CD4+T淋巴细胞的比例,验证N6-CAR-T细胞的杀伤作用,实验结果如图5所示。
结果表明,以未经CAR分子改造的CD8+T细胞组为参照,N6-CAR-T细胞组能清除其中99.5%的HIV-1感染的细胞,表现出显著的杀伤效果,充分展示了N6-CAR-T细胞的特异性和高效性。
实施例6:CAR-T淋巴细胞在体内杀灭感染HIV病毒细胞的活性检测
为了进一步证明Anti-gp120CAR-T淋巴细胞能否在体内清除HIV感染的细胞,我们将带有荧光基因的NL4-3-EGFP病毒(1x106pg p24/mouse)静脉注射到人源化小鼠BLT体内,感染小鼠同时,从健康志愿者分离PBMC然后分离CD8+T细胞,转导N6-CAR慢病毒,体外扩增10天后,计数后用500μl PBS重悬,按1x107CD8+T/kg的剂量静脉回输。两周后,从小鼠体内收集脾脏,放入包埋剂中制备冷冻切片。制备大于20张的10μm厚度的冷冻切片,在荧光共聚焦显微镜下照相,将相片利用Velocity 5.0软件进行量化分析(图6A)。同时,以收集到的部分脾脏细胞制备单细胞悬液,取5x106细胞于DNAzol来提取基因组DNA,利用Nested-QPCR定量前病毒的拷贝数来评估体内所有感染HIV的细胞数目(图6B)。
结果表明,与未接收CAR-T细胞治疗的对照组相比,病毒蛋白表达水平和病毒基因组水平显著性各减少97.1%,证实了CAR-T细胞能在体内进行有效地裂解和清除HIV感染的细胞,为CAR-T细胞进行人体临床测试奠定理论基础。
SEQUENCE LISTING
<110> 武汉云谷生物医药科技有限公司
<120> 一种治疗HIV感染的嵌合抗原受体的重组基因构建及其应用
<130> 2017
<160> 6
<170> PatentIn version 3.3
<210> 1
<211> 786
<212> DNA
<213> N6
<400> 1
atgctgctgc tggtgaccag cctgctgctg tgcgagctgc cccaccccgc ccccctgctg 60
atcccccgag cgcacctggt acaatcaggg actgcgatga agaaaccggg ggcctcagta 120
agagtctcct gccagacctc tggatacacc tttaccgccc acatattatt ttggttccga 180
caggcccccg ggcgaggact tgagtgggtg gggtggatca agccacaata tggggccgtg 240
aattttggtg gtggttttcg ggacagggtc acattgactc gagacgtata tagagagatt 300
gcgtacatgg acatcagagg ccttaaacct gacgacacgg ccgtctatta ctgtgcgaga 360
gaccgttcct atggcgactc ctcttgggcc ttagatgcct ggggacaggg aacgacggtc 420
gtcgtctccg cgggcggagg gggttcaggt ggaggaggct ctggcggtgg cggaagctac 480
atccacgtga cccagtctcc gtcctccctg tctgtgtcta ttggagacag agtcaccatc 540
aattgccaga cgagtcaggg tgttggcagt gacctacatt ggtatcaaca caaaccgggg 600
agagccccta aactcttgat ccaccatacc tcttctgtgg aagacggtgt cccctcaaga 660
ttcagcggct ctggatttca cacatctttt aatctgacca tcagcgacct acaggctgac 720
gacattgcca catattactg tcaagtttta caatttttcg gccgagggag tcgactccat 780
attaaa 786
<210> 2
<211> 262
<212> PRT
<213> 人工序列
<400> 2
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Arg Ala His Leu Val Gln Ser Gly Thr Ala
20 25 30
Met Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Gln Thr Ser Gly
35 40 45
Tyr Thr Phe Thr Ala His Ile Leu Phe Trp Phe Arg Gln Ala Pro Gly
50 55 60
Arg Gly Leu Glu Trp Val Gly Trp Ile Lys Pro Gln Tyr Gly Ala Val
65 70 75 80
Asn Phe Gly Gly Gly Phe Arg Asp Arg Val Thr Leu Thr Arg Asp Val
85 90 95
Tyr Arg Glu Ile Ala Tyr Met Asp Ile Arg Gly Leu Lys Pro Asp Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Gly Asp Ser Ser
115 120 125
Trp Ala Leu Asp Ala Trp Gly Gln Gly Thr Thr Val Val Val Ser Ala
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Tyr
145 150 155 160
Ile His Val Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ile Gly Asp
165 170 175
Arg Val Thr Ile Asn Cys Gln Thr Ser Gln Gly Val Gly Ser Asp Leu
180 185 190
His Trp Tyr Gln His Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile His
195 200 205
His Thr Ser Ser Val Glu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser
210 215 220
Gly Phe His Thr Ser Phe Asn Leu Thr Ile Ser Asp Leu Gln Ala Asp
225 230 235 240
Asp Ile Ala Thr Tyr Tyr Cys Gln Val Leu Gln Phe Phe Gly Arg Gly
245 250 255
Ser Arg Leu His Ile Lys
260
<210> 3
<211> 1590
<212> DNA
<213> 人工序列
<400> 3
atgctgctgc tggtgaccag cctgctgctg tgcgagctgc cccaccccgc ccccctgctg 60
atcccccgag cgcacctggt acaatcaggg actgcgatga agaaaccggg ggcctcagta 120
agagtctcct gccagacctc tggatacacc tttaccgccc acatattatt ttggttccga 180
caggcccccg ggcgaggact tgagtgggtg gggtggatca agccacaata tggggccgtg 240
aattttggtg gtggttttcg ggacagggtc acattgactc gagacgtata tagagagatt 300
gcgtacatgg acatcagagg ccttaaacct gacgacacgg ccgtctatta ctgtgcgaga 360
gaccgttcct atggcgactc ctcttgggcc ttagatgcct ggggacaggg aacgacggtc 420
gtcgtctccg cgggcggagg gggttcaggt ggaggaggct ctggcggtgg cggaagctac 480
atccacgtga cccagtctcc gtcctccctg tctgtgtcta ttggagacag agtcaccatc 540
aattgccaga cgagtcaggg tgttggcagt gacctacatt ggtatcaaca caaaccgggg 600
agagccccta aactcttgat ccaccatacc tcttctgtgg aagacggtgt cccctcaaga 660
ttcagcggct ctggatttca cacatctttt aatctgacca tcagcgacct acaggctgac 720
gacattgcca catattactg tcaagtttta caatttttcg gccgagggag tcgactccat 780
attaaaacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag 840
cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg 900
gggctggact tcgcctgtga tttttgggtg ctggtggtgg ttggtggagt cctggcttgc 960
tatagcttgc tagtaacagt ggcctttatt attttctggg tgaggagtaa gaggagcagg1020
ctcctgcaca gtgactacat gaacatgact ccccgccgcc ccgggcccac ccgcaagcat1080
taccagccct atgccccacc acgcgacttc gcagcctatc gctccaaacg gggcagaaag1140
aaactcctgt atatattcaa acaaccattt atgagaccag tacaaactac tcaagaggaa1200
gatggctgta gctgccgatt tccagaagaa gaagaaggag gatgtgaact gagagtgaag1260
ttcagcagga gcgcagacgc ccccgcgtac cagcagggcc agaaccagct ctataacgag1320
ctcaatctag gacgaagaga ggagtacgat gttttggaca agagacgtgg ccgggaccct1380
gagatggggg gaaagccgag aaggaagaac cctcaggaag gcctgtacaa tgaactgcag1440
aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc1500
aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc1560
cttcacatgc aggccctgcc ccctcgctaa 1590
<210> 4
<211> 529
<212> PRT
<213> 人工序列
<400> 4
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Arg Ala His Leu Val Gln Ser Gly Thr Ala
20 25 30
Met Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Gln Thr Ser Gly
35 40 45
Tyr Thr Phe Thr Ala His Ile Leu Phe Trp Phe Arg Gln Ala Pro Gly
50 55 60
Arg Gly Leu Glu Trp Val Gly Trp Ile Lys Pro Gln Tyr Gly Ala Val
65 70 75 80
Asn Phe Gly Gly Gly Phe Arg Asp Arg Val Thr Leu Thr Arg Asp Val
85 90 95
Tyr Arg Glu Ile Ala Tyr Met Asp Ile Arg Gly Leu Lys Pro Asp Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Gly Asp Ser Ser
115 120 125
Trp Ala Leu Asp Ala Trp Gly Gln Gly Thr Thr Val Val Val Ser Ala
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Tyr
145 150 155 160
Ile His Val Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ile Gly Asp
165 170 175
Arg Val Thr Ile Asn Cys Gln Thr Ser Gln Gly Val Gly Ser Asp Leu
180 185 190
His Trp Tyr Gln His Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile His
195 200 205
His Thr Ser Ser Val Glu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser
210 215 220
Gly Phe His Thr Ser Phe Asn Leu Thr Ile Ser Asp Leu Gln Ala Asp
225 230 235 240
Asp Ile Ala Thr Tyr Tyr Cys Gln Val Leu Gln Phe Phe Gly Arg Gly
245 250 255
Ser Arg Leu His Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr
260 265 270
Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala
275 280 285
Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe
290 295 300
Ala Cys Asp Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365
Asp Phe Ala Ala Tyr Arg Ser Lys Arg Gly Arg Lys Lys Leu Leu Tyr
370 375 380
Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
385 390 395 400
Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu
405 410 415
Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
420 425 430
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
435 440 445
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
450 455 460
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
465 470 475 480
Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
485 490 495
Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
500 505 510
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
515 520 525
Arg
<210> 5
<211> 9251
<212> DNA
<213> 人工序列
<400> 5
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagcgcgtt ttgcctgtac tgggtctctc 840
tggttagacc agatctgagc ctgggagctc tctggctaac tagggaaccc actgcttaag 900
cctcaataaa gcttgccttg agtgcttcaa gtagtgtgtg cccgtctgtt gtgtgactct 960
ggtaactaga gatccctcag acccttttag tcagtgtgga aaatctctag cagtggcgcc1020
cgaacaggga cctgaaagcg aaagggaaac cagagctctc tcgacgcagg actcggcttg1080
ctgaagcgcg cacggcaaga ggcgaggggc ggcgactggt gagtacgcca aaaattttga1140
ctagcggagg ctagaaggag agagatgggt gcgagagcgt cagtattaag cgggggagaa1200
ttagatcgcg atgggaaaaa attcggttaa ggccaggggg aaagaaaaaa tataaattaa1260
aacatatagt atgggcaagc agggagctag aacgattcgc agttaatcct ggcctgttag1320
aaacatcaga aggctgtaga caaatactgg gacagctaca accatccctt cagacaggat1380
cagaagaact tagatcatta tataatacag tagcaaccct ctattgtgtg catcaaagga1440
tagagataaa agacaccaag gaagctttag acaagataga ggaagagcaa aacaaaagta1500
agaccaccgc acagcaagcg gccgctgatc ttcagacctg gaggaggaga tatgagggac1560
aattggagaa gtgaattata taaatataaa gtagtaaaaa ttgaaccatt aggagtagca1620
cccaccaagg caaagagaag agtggtgcag agagaaaaaa gagcagtggg aataggagct1680
ttgttccttg ggttcttggg agcagcagga agcactatgg gcgcagcctc aatgacgctg1740
acggtacagg ccagacaatt attgtctggt atagtgcagc agcagaacaa tttgctgagg1800
gctattgagg cgcaacagca tctgttgcaa ctcacagtct ggggcatcaa gcagctccag1860
gcaagaatcc tggctgtgga aagataccta aaggatcaac agctcctggg gatttggggt1920
tgctctggaa aactcatttg caccactgct gtgccttgga atgctagttg gagtaataaa1980
tctctggaac agatctggaa tcacacgacc tggatggagt gggacagaga aattaacaat2040
tacacaagct taatacactc cttaattgaa gaatcgcaaa accagcaaga aaagaatgaa2100
caagaattat tggaattaga taaatgggca agtttgtgga attggtttaa cataacaaat2160
tggctgtggt atataaaatt attcataatg atagtaggag gcttggtagg tttaagaata2220
gtttttgctg tactttctat agtgaataga gttaggcagg gatattcacc attatcgttt2280
cagacccacc tcccaacccc gaggggaccc gacaggcccg aaggaataga agaagaaggt2340
ggagagagag acagagacag atccattcga ttagtgaacg gatcttccat cgaattcctg2400
cagcccgggg gatctaaaag aaaagggggg attggggggt acagtgcagg ggaaagaata2460
gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaatt2520
caaaattttc gggtttatta cagggacagc agagatccag tttatcgatg agtaattcat2580
acaaaaggac tcgcccctgc cttggggaat cccagggacc gtcgttaaac tcccactaac2640
gtagaaccca gagatcgctg cgttcccgcc ccctcacccg cccgctctcg tcatcactga2700
ggtggagaag agcatgcgtg aggctccggt gcccgtcagt gggcagagcg cacatcgccc2760
acagtccccg agaagttggg gggaggggtc ggcaattgaa ccggtgccta gagaaggtgg2820
cgcggggtaa actgggaaag tgatgtcgtg tactggctcc gcctttttcc cgagggtggg2880
ggagaaccgt atataagtgc agtagtcgcc gtgaacgttc tttttcgcaa cgggtttgcc2940
gccagaacac aggtaagtgc cgtgtgtggt tcccgcgggc ctggcctctt tacgggttat3000
ggcccttgcg tgccttgaat tacttccacg cccctggctg cagtacgtga ttcttgatcc3060
cgagcttcgg gttggaagtg ggtgggagag ttcgaggcct tgcgcttaag gagccccttc3120
gcctcgtgct tgagttgagg cctggcttgg gcgctggggc cgccgcgtgc gaatctggtg3180
gcaccttcgc gcctgtctcg ctgctttcga taagtctcta gccatttaaa atttttgatg3240
acctgctgcg acgctttttt tctggcaaga tagtcttgta aatgcgggcc aagatctgca3300
cactggtatt tcggtttttg gggccgcggg cggcgacggg gcccgtgcgt cccagcgcac3360
atgttcggcg aggcggggcc tgcgagcgcg gccaccgaga atcggacggg ggtagtctca3420
agctggccgg cctgctctgg tgcctggcct cgcgccgccg tgtatcgccc cgccctgggc3480
ggcaaggctg gcccggtcgg caccagttgc gtgagcggaa agatggccgc ttcccggccc3540
tgctgcaggg agctcaaaat ggaggacgcg gcgctcggga gagcgggcgg gtgagtcacc3600
cacacaaagg aaaagggcct ttccgtcctc agccgtcgct tcatgtgact ccacggagta3660
ccgggcgccg tccaggcacc tcgattagtt ctcgagcttt tggagtacgt cgtctttagg3720
ttggggggag gggttttatg cgatggagtt tccccacact gagtgggtgg agactgaagt3780
taggccagct tggcacttga tgtaattctc cttggaattt gccctttttg agtttggatc3840
ttggttcatt ctcaagcctc agacagtggt tcaaagtttt tttcttccat ttcaggtgtc3900
gtgaggatct atttccggtg aattcgccac cacgcgtctg gaacaatcaa cctctggatt3960
acaaaatttg tgaaagattg actggtattc ttaactatgt tgctcctttt acgctatgtg4020
gatacgctgc tttaatgcct ttgtatcatg ctattgcttc ccgtatggct ttcattttct4080
cctccttgta taaatcctgg ttgctgtctc tttatgagga gttgtggccc gttgtcaggc4140
aacgtggcgt ggtgtgcact gtgtttgctg acgcaacccc cactggttgg ggcattgcca4200
ccacctgtca gctcctttcc gggactttcg ctttccccct ccctattgcc acggcggaac4260
tcatcgccgc ctgccttgcc cgctgctgga caggggctcg gctgttgggc actgacaatt4320
ccgtggtgtt gtcggggaag ctgacgtcct ttccatggct gctcgcctgt gttgccacct4380
ggattctgcg cgggacgtcc ttctgctacg tcccttcggc cctcaatcca gcggaccttc4440
cttcccgcgg cctgctgccg gctctgcggc ctcttccgcg tcttcgcctt cgccctcaga4500
cgagtcggat ctccctttgg gccgcctccc cgcatcgata ccgtcgagac ctggaaaaac4560
atggagcaat cacaagtagc aacacagcag ctaccaatgc tgcttgtgcc tggctagaag4620
cacaagagga ggaggaggtg ggttttccag tcacacctca ggtaccttta agaccaatga4680
cttacaaggc agctgtagat cttagccact ttttaaaaga aaagggggga ctggaagggc4740
taattcactc ccaacgaaga caagatatcc ttgatctgtg gatctaccac acacaaggct4800
acttccctga ttggcagaac tacacaccag ggccagggat cagatatcca ctgacctttg4860
gatggtgcta caagctagta ccagttgagc aagagaaggt agaagaagcc aatgaaggag4920
agaacacccg cttgttacac cctgtgagcc tgcatgggat ggatgacccg gagagagaag4980
tattagagtg gaggtttgac agccgcctag catttcatca catggcccga gagctgcatc5040
cggactgtac tgggtctctc tggttagacc agatctgagc ctgggagctc tctggctaac5100
tagggaaccc actgcttaag cctcaataaa gcttgccttg agtgcttcaa gtagtgtgtg5160
cccgtctgtt gtgtgactct ggtaactaga gatccctcag acccttttag tcagtgtgga5220
aaatctctag cagggcccgt ttaaacccgc tgatcagcct cgactgtgcc ttctagttgc5280
cagccatctg ttgtttgccc ctcccccgtg ccttccttga ccctggaagg tgccactccc5340
actgtccttt cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct5400
attctggggg gtggggtggg gcaggacagc aagggggagg attgggaaga caatagcagg5460
catgctgggg atgcggtggg ctctatggct tctgaggcgg aaagaaccag ctggggctct5520
agggggtatc cccacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg5580
cgcagcgtga ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct5640
tcctttctcg ccacgttcgc cggctttccc cgtcaagctc taaatcgggg catcccttta5700
gggttccgat ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt5760
tcacgtagtg ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg5820
ttctttaata gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat5880
tcttttgatt tataagggat tttggggatt tcggcctatt ggttaaaaaa tgagctgatt5940
taacaaaaat ttaacgcgaa ttaattctgt ggaatgtgtg tcagttaggg tgtggaaagt6000
ccccaggctc cccaggcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc6060
aggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat6120
tagtcagcaa ccatagtccc gcccctaact ccgcccatcc cgcccctaac tccgcccagt6180
tccgcccatt ctccgcccca tggctgacta atttttttta tttatgcaga ggccgaggcc6240
gcctctgcct ctgagctatt ccagaagtag tgaggaggct tttttggagg cctaggcttt6300
tgcaaaaagc tcccgggagc ttgtatatcc attttcggat ctgatcagca cgtgttgaca6360
attaatcatc ggcatagtat atcggcatag tataatacga caaggtgagg aactaaacca6420
tggccaagtt gaccagtgcc gttccggtgc tcaccgcgcg cgacgtcgcc ggagcggtcg6480
agttctggac cgaccggctc gggttctccc gggacttcgt ggaggacgac ttcgccggtg6540
tggtccggga cgacgtgacc ctgttcatca gcgcggtcca ggaccaggtg gtgccggaca6600
acaccctggc ctgggtgtgg gtgcgcggcc tggacgagct gtacgccgag tggtcggagg6660
tcgtgtccac gaacttccgg gacgcctccg ggccggccat gaccgagatc ggcgagcagc6720
cgtgggggcg ggagttcgcc ctgcgcgacc cggccggcaa ctgcgtgcac ttcgtggccg6780
aggagcagga ctgacacgtg ctacgagatt tcgattccac cgccgccttc tatgaaaggt6840
tgggcttcgg aatcgttttc cgggacgccg gctggatgat cctccagcgc ggggatctca6900
tgctggagtt cttcgcccac cccaacttgt ttattgcagc ttataatggt tacaaataaa6960
gcaatagcat cacaaatttc acaaataaag catttttttc actgcattct agttgtggtt7020
tgtccaaact catcaatgta tcttatcatg tctgtatacc gtcgacctct agctagagct7080
tggcgtaatc atggtcatag ctgtttcctg tgtgaaattg ttatccgctc acaattccac7140
acaacatacg agccggaagc ataaagtgta aagcctgggg tgcctaatga gtgagctaac7200
tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg tcgtgccagc7260
tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg cgctcttccg7320
cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc7380
actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt7440
gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc7500
ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa7560
acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc7620
ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg7680
cgctttctca atgctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc7740
tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc7800
gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca7860
ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact7920
acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg7980
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt8040
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct8100
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga8160
gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa8220
tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac8280
ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga8340
taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc8400
cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca8460
gaagtggtcc tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta8520
gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg8580
tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc8640
gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg8700
ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt8760
ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt8820
cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca atacgggata8880
ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt tcttcggggc8940
gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc actcgtgcac9000
ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa9060
ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct9120
tcctttttca atattattga agcatttatc agggttattg tctcatgagc ggatacatat9180
ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc9240
cacctgacgt c 9251
<210> 6
<211> 10841
<212> DNA
<213> 人工序列
<400> 6
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagcgcgtt ttgcctgtac tgggtctctc 840
tggttagacc agatctgagc ctgggagctc tctggctaac tagggaaccc actgcttaag 900
cctcaataaa gcttgccttg agtgcttcaa gtagtgtgtg cccgtctgtt gtgtgactct 960
ggtaactaga gatccctcag acccttttag tcagtgtgga aaatctctag cagtggcgcc1020
cgaacaggga cctgaaagcg aaagggaaac cagagctctc tcgacgcagg actcggcttg1080
ctgaagcgcg cacggcaaga ggcgaggggc ggcgactggt gagtacgcca aaaattttga1140
ctagcggagg ctagaaggag agagatgggt gcgagagcgt cagtattaag cgggggagaa1200
ttagatcgcg atgggaaaaa attcggttaa ggccaggggg aaagaaaaaa tataaattaa1260
aacatatagt atgggcaagc agggagctag aacgattcgc agttaatcct ggcctgttag1320
aaacatcaga aggctgtaga caaatactgg gacagctaca accatccctt cagacaggat1380
cagaagaact tagatcatta tataatacag tagcaaccct ctattgtgtg catcaaagga1440
tagagataaa agacaccaag gaagctttag acaagataga ggaagagcaa aacaaaagta1500
agaccaccgc acagcaagcg gccgctgatc ttcagacctg gaggaggaga tatgagggac1560
aattggagaa gtgaattata taaatataaa gtagtaaaaa ttgaaccatt aggagtagca1620
cccaccaagg caaagagaag agtggtgcag agagaaaaaa gagcagtggg aataggagct1680
ttgttccttg ggttcttggg agcagcagga agcactatgg gcgcagcctc aatgacgctg1740
acggtacagg ccagacaatt attgtctggt atagtgcagc agcagaacaa tttgctgagg1800
gctattgagg cgcaacagca tctgttgcaa ctcacagtct ggggcatcaa gcagctccag1860
gcaagaatcc tggctgtgga aagataccta aaggatcaac agctcctggg gatttggggt1920
tgctctggaa aactcatttg caccactgct gtgccttgga atgctagttg gagtaataaa1980
tctctggaac agatctggaa tcacacgacc tggatggagt gggacagaga aattaacaat2040
tacacaagct taatacactc cttaattgaa gaatcgcaaa accagcaaga aaagaatgaa2100
caagaattat tggaattaga taaatgggca agtttgtgga attggtttaa cataacaaat2160
tggctgtggt atataaaatt attcataatg atagtaggag gcttggtagg tttaagaata2220
gtttttgctg tactttctat agtgaataga gttaggcagg gatattcacc attatcgttt2280
cagacccacc tcccaacccc gaggggaccc gacaggcccg aaggaataga agaagaaggt2340
ggagagagag acagagacag atccattcga ttagtgaacg gatcttccat cgaattcctg2400
cagcccgggg gatctaaaag aaaagggggg attggggggt acagtgcagg ggaaagaata2460
gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaatt2520
caaaattttc gggtttatta cagggacagc agagatccag tttatcgatg agtaattcat2580
acaaaaggac tcgcccctgc cttggggaat cccagggacc gtcgttaaac tcccactaac2640
gtagaaccca gagatcgctg cgttcccgcc ccctcacccg cccgctctcg tcatcactga2700
ggtggagaag agcatgcgtg aggctccggt gcccgtcagt gggcagagcg cacatcgccc2760
acagtccccg agaagttggg gggaggggtc ggcaattgaa ccggtgccta gagaaggtgg2820
cgcggggtaa actgggaaag tgatgtcgtg tactggctcc gcctttttcc cgagggtggg2880
ggagaaccgt atataagtgc agtagtcgcc gtgaacgttc tttttcgcaa cgggtttgcc2940
gccagaacac aggtaagtgc cgtgtgtggt tcccgcgggc ctggcctctt tacgggttat3000
ggcccttgcg tgccttgaat tacttccacg cccctggctg cagtacgtga ttcttgatcc3060
cgagcttcgg gttggaagtg ggtgggagag ttcgaggcct tgcgcttaag gagccccttc3120
gcctcgtgct tgagttgagg cctggcttgg gcgctggggc cgccgcgtgc gaatctggtg3180
gcaccttcgc gcctgtctcg ctgctttcga taagtctcta gccatttaaa atttttgatg3240
acctgctgcg acgctttttt tctggcaaga tagtcttgta aatgcgggcc aagatctgca3300
cactggtatt tcggtttttg gggccgcggg cggcgacggg gcccgtgcgt cccagcgcac3360
atgttcggcg aggcggggcc tgcgagcgcg gccaccgaga atcggacggg ggtagtctca3420
agctggccgg cctgctctgg tgcctggcct cgcgccgccg tgtatcgccc cgccctgggc3480
ggcaaggctg gcccggtcgg caccagttgc gtgagcggaa agatggccgc ttcccggccc3540
tgctgcaggg agctcaaaat ggaggacgcg gcgctcggga gagcgggcgg gtgagtcacc3600
cacacaaagg aaaagggcct ttccgtcctc agccgtcgct tcatgtgact ccacggagta3660
ccgggcgccg tccaggcacc tcgattagtt ctcgagcttt tggagtacgt cgtctttagg3720
ttggggggag gggttttatg cgatggagtt tccccacact gagtgggtgg agactgaagt3780
taggccagct tggcacttga tgtaattctc cttggaattt gccctttttg agtttggatc3840
ttggttcatt ctcaagcctc agacagtggt tcaaagtttt tttcttccat ttcaggtgtc3900
gtgaggatct atttccggtg aattcgccac catgctgctg ctggtgacca gcctgctgct3960
gtgcgagctg ccccaccccg cccccctgct gatcccccga gcgcacctgg tacaatcagg4020
gactgcgatg aagaaaccgg gggcctcagt aagagtctcc tgccagacct ctggatacac4080
ctttaccgcc cacatattat tttggttccg acaggccccc gggcgaggac ttgagtgggt4140
ggggtggatc aagccacaat atggggccgt gaattttggt ggtggttttc gggacagggt4200
cacattgact cgagacgtat atagagagat tgcgtacatg gacatcagag gccttaaacc4260
tgacgacacg gccgtctatt actgtgcgag agaccgttcc tatggcgact cctcttgggc4320
cttagatgcc tggggacagg gaacgacggt cgtcgtctcc gcgggcggag ggggttcagg4380
tggaggaggc tctggcggtg gcggaagcta catccacgtg acccagtctc cgtcctccct4440
gtctgtgtct attggagaca gagtcaccat caattgccag acgagtcagg gtgttggcag4500
tgacctacat tggtatcaac acaaaccggg gagagcccct aaactcttga tccaccatac4560
ctcttctgtg gaagacggtg tcccctcaag attcagcggc tctggatttc acacatcttt4620
taatctgacc atcagcgacc tacaggctga cgacattgcc acatattact gtcaagtttt4680
acaatttttc ggccgaggga gtcgactcca tattaaaacc acgacgccag cgccgcgacc4740
accaacaccg gcgcccacca tcgcgtcgca gcccctgtcc ctgcgcccag aggcgtgccg4800
gccagcggcg gggggcgcag tgcacacgag ggggctggac ttcgcctgtg atttttgggt4860
gctggtggtg gttggtggag tcctggcttg ctatagcttg ctagtaacag tggcctttat4920
tattttctgg gtgaggagta agaggagcag gctcctgcac agtgactaca tgaacatgac4980
tccccgccgc cccgggccca cccgcaagca ttaccagccc tatgccccac cacgcgactt5040
cgcagcctat cgctccaaac ggggcagaaa gaaactcctg tatatattca aacaaccatt5100
tatgagacca gtacaaacta ctcaagagga agatggctgt agctgccgat ttccagaaga5160
agaagaagga ggatgtgaac tgagagtgaa gttcagcagg agcgcagacg cccccgcgta5220
ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag aggagtacga5280
tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga gaaggaagaa5340
ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg cctacagtga5400
gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt accagggtct5460
cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc cccctcgcta5520
aacgcgtctg gaacaatcaa cctctggatt acaaaatttg tgaaagattg actggtattc5580
ttaactatgt tgctcctttt acgctatgtg gatacgctgc tttaatgcct ttgtatcatg5640
ctattgcttc ccgtatggct ttcattttct cctccttgta taaatcctgg ttgctgtctc5700
tttatgagga gttgtggccc gttgtcaggc aacgtggcgt ggtgtgcact gtgtttgctg5760
acgcaacccc cactggttgg ggcattgcca ccacctgtca gctcctttcc gggactttcg5820
ctttccccct ccctattgcc acggcggaac tcatcgccgc ctgccttgcc cgctgctgga5880
caggggctcg gctgttgggc actgacaatt ccgtggtgtt gtcggggaag ctgacgtcct5940
ttccatggct gctcgcctgt gttgccacct ggattctgcg cgggacgtcc ttctgctacg6000
tcccttcggc cctcaatcca gcggaccttc cttcccgcgg cctgctgccg gctctgcggc6060
ctcttccgcg tcttcgcctt cgccctcaga cgagtcggat ctccctttgg gccgcctccc6120
cgcatcgata ccgtcgagac ctggaaaaac atggagcaat cacaagtagc aacacagcag6180
ctaccaatgc tgcttgtgcc tggctagaag cacaagagga ggaggaggtg ggttttccag6240
tcacacctca ggtaccttta agaccaatga cttacaaggc agctgtagat cttagccact6300
ttttaaaaga aaagggggga ctggaagggc taattcactc ccaacgaaga caagatatcc6360
ttgatctgtg gatctaccac acacaaggct acttccctga ttggcagaac tacacaccag6420
ggccagggat cagatatcca ctgacctttg gatggtgcta caagctagta ccagttgagc6480
aagagaaggt agaagaagcc aatgaaggag agaacacccg cttgttacac cctgtgagcc6540
tgcatgggat ggatgacccg gagagagaag tattagagtg gaggtttgac agccgcctag6600
catttcatca catggcccga gagctgcatc cggactgtac tgggtctctc tggttagacc6660
agatctgagc ctgggagctc tctggctaac tagggaaccc actgcttaag cctcaataaa6720
gcttgccttg agtgcttcaa gtagtgtgtg cccgtctgtt gtgtgactct ggtaactaga6780
gatccctcag acccttttag tcagtgtgga aaatctctag cagggcccgt ttaaacccgc6840
tgatcagcct cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg6900
ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt6960
gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg gcaggacagc7020
aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg ctctatggct7080
tctgaggcgg aaagaaccag ctggggctct agggggtatc cccacgcgcc ctgtagcggc7140
gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga ccgctacact tgccagcgcc7200
ctagcgcccg ctcctttcgc tttcttccct tcctttctcg ccacgttcgc cggctttccc7260
cgtcaagctc taaatcgggg catcccttta gggttccgat ttagtgcttt acggcacctc7320
gaccccaaaa aacttgatta gggtgatggt tcacgtagtg ggccatcgcc ctgatagacg7380
gtttttcgcc ctttgacgtt ggagtccacg ttctttaata gtggactctt gttccaaact7440
ggaacaacac tcaaccctat ctcggtctat tcttttgatt tataagggat tttggggatt7500
tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa ttaattctgt7560
ggaatgtgtg tcagttaggg tgtggaaagt ccccaggctc cccaggcagg cagaagtatg7620
caaagcatgc atctcaatta gtcagcaacc aggtgtggaa agtccccagg ctccccagca7680
ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa ccatagtccc gcccctaact7740
ccgcccatcc cgcccctaac tccgcccagt tccgcccatt ctccgcccca tggctgacta7800
atttttttta tttatgcaga ggccgaggcc gcctctgcct ctgagctatt ccagaagtag7860
tgaggaggct tttttggagg cctaggcttt tgcaaaaagc tcccgggagc ttgtatatcc7920
attttcggat ctgatcagca cgtgttgaca attaatcatc ggcatagtat atcggcatag7980
tataatacga caaggtgagg aactaaacca tggccaagtt gaccagtgcc gttccggtgc8040
tcaccgcgcg cgacgtcgcc ggagcggtcg agttctggac cgaccggctc gggttctccc8100
gggacttcgt ggaggacgac ttcgccggtg tggtccggga cgacgtgacc ctgttcatca8160
gcgcggtcca ggaccaggtg gtgccggaca acaccctggc ctgggtgtgg gtgcgcggcc8220
tggacgagct gtacgccgag tggtcggagg tcgtgtccac gaacttccgg gacgcctccg8280
ggccggccat gaccgagatc ggcgagcagc cgtgggggcg ggagttcgcc ctgcgcgacc8340
cggccggcaa ctgcgtgcac ttcgtggccg aggagcagga ctgacacgtg ctacgagatt8400
tcgattccac cgccgccttc tatgaaaggt tgggcttcgg aatcgttttc cgggacgccg8460
gctggatgat cctccagcgc ggggatctca tgctggagtt cttcgcccac cccaacttgt8520
ttattgcagc ttataatggt tacaaataaa gcaatagcat cacaaatttc acaaataaag8580
catttttttc actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg8640
tctgtatacc gtcgacctct agctagagct tggcgtaatc atggtcatag ctgtttcctg8700
tgtgaaattg ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgta8760
aagcctgggg tgcctaatga gtgagctaac tcacattaat tgcgttgcgc tcactgcccg8820
ctttccagtc gggaaacctg tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga8880
gaggcggttt gcgtattggg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg8940
tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag9000
aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc9060
gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac gagcatcaca9120
aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt9180
ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc9240
tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca atgctcacgc tgtaggtatc9300
tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc9360
ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta agacacgact9420
tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggtat gtaggcggtg9480
ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggta9540
tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca9600
aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa9660
aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaacg9720
aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc9780
ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg9840
acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat9900
ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg9960
gccccagtgc tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa10020
taaaccagcc agccggaagg gccgagcgca gaagtggtcc tgcaacttta tccgcctcca10080
tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc10140
gcaacgttgt tgccattgct acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt10200
cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa10260
aagcggttag ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat10320
cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct10380
tttctgtgac tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga10440
gttgctcttg cccggcgtca atacgggata ataccgcgcc acatagcaga actttaaaag10500
tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga10560
gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca10620
ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg10680
cgacacggaa atgttgaata ctcatactct tcctttttca atattattga agcatttatc10740
agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag10800
gggttccgcg cacatttccc cgaaaagtgc cacctgacgt c 10841

Claims (7)

1.一种治疗HIV感染的嵌合型抗原受体N6-CAR,其特征在于:该嵌合型抗原受体是通过N端到C端顺次拼接信号肽、单链抗体ScFv、CD8hinge、白细胞抗原分化群分子跨膜区CD28-TM及其细胞内结构域(ICD)、4-1BB和白细胞抗原分化群3的ζ链CD3得到的,所得到的嵌合型抗原受体的氨基酸序列如SEQ ID NO.4所示;所述单链抗体ScFv能够识别HIV病毒感染细胞表面的gp120,是通过串联针对HIV病毒感染细胞表面的gp120的抗体轻链、重链可变区而得,单链抗体ScFv作为整个CAR分子的胞外结合结构域,其氨基酸序列如SEQ ID NO.2所示。
2.根据权利要求1所述的一种治疗HIV感染的嵌合型抗原受体N6-CAR,其特征在于:编码单链抗体ScFv基因的核苷酸序列如SEQ ID NO.1所示。
3.编码权利要求1所述的嵌合型抗原受体的基因,其特征在于:其核苷酸序列如SEQ IDNO.3所示。
4.一种含有并能表达氨基酸序列为SEQ ID NO.4所示的嵌合型抗原受体的编码基因的表达载体,其特征在于:所述载体为以PTK881载体为骨架,将CMV启动子替换成EF-1α启动子后改造成的PTK-EF1α-N6载体,其核苷酸序列如SEQ ID NO.5所示。
5.一种基因修饰的CD8+T淋巴细胞,其特征在于:是将权利要求4所述的PTK-EF1α-N6表达载体转染293T细胞所得的慢病毒载体转导CD8+T淋巴细胞,从而获得的能表达权利要求1所述的嵌合型抗原受体的基因工程化的T-淋巴细胞。
6.根据权利要求5所述的基因修饰的CD8+T细胞,其特征在于:由以下方法制备得到:从外周血分离PBMC后再用磁珠阳选获得CD8+T细胞,经anti-CD3/28磁珠(细胞与磁珠比例为1:3)刺激12小时后,加入重组有权利要求1-2任一所述嵌合型抗原受体N6-CAR分子的慢病毒感染4小时后补液(MOI=5),从病毒感染后第三天开始,细胞计数并根据细胞状态和增殖情况补加培养基,细胞浓度调整至0.6x106/ml,并补充IL-2100U/mL,进一步扩增细胞直到满足回输的细胞数。
7.一种如权利要求5-6任一所述的基因修饰的CD8+T淋巴细胞的用途,其特征在于:所述基因修饰的CD8+T淋巴细胞应用于制备抗HIV感染的活细胞药物。
CN201710507860.8A 2017-06-28 2017-06-28 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用 Active CN107098969B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201710507860.8A CN107098969B (zh) 2017-06-28 2017-06-28 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
JP2019538366A JP6890664B2 (ja) 2017-06-28 2017-08-28 Hiv感染を治療するキメラ抗原受容体の組換え遺伝子構築およびその応用
EP17915822.5A EP3511347A4 (en) 2017-06-28 2017-08-28 CONSTRUCTION OF A RECOMBINED CHIMERIC ANTIGEN RECEPTOR GENE FOR THE TREATMENT OF HIV INFECTION, AND APPLICATION THEREOF
PCT/CN2017/099261 WO2019000620A1 (zh) 2017-06-28 2017-08-28 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
US16/317,514 US20190389940A1 (en) 2017-06-28 2017-08-28 Construction and application of recombinant gene for chimeric antigen receptor for treating hiv infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710507860.8A CN107098969B (zh) 2017-06-28 2017-06-28 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用

Publications (2)

Publication Number Publication Date
CN107098969A CN107098969A (zh) 2017-08-29
CN107098969B true CN107098969B (zh) 2018-10-12

Family

ID=59664361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710507860.8A Active CN107098969B (zh) 2017-06-28 2017-06-28 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用

Country Status (5)

Country Link
US (1) US20190389940A1 (zh)
EP (1) EP3511347A4 (zh)
JP (1) JP6890664B2 (zh)
CN (1) CN107098969B (zh)
WO (1) WO2019000620A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107619820A (zh) * 2017-09-07 2018-01-23 河南大学淮河医院 Hiv病毒潜伏库双靶向性嵌合抗原受体修饰的t细胞及其制备方法和应用
CN107904259A (zh) * 2017-11-01 2018-04-13 上海隆耀生物科技有限公司 一种治疗艾滋病合并淋巴瘤的car‑t细胞及其制备方法和应用
CN107987173B (zh) * 2017-11-30 2021-07-13 山东兴瑞生物科技有限公司 双靶点嵌合抗原受体、其编码基因、具有该基因质粒、免疫t效应细胞及hiv-1应用
CN108059675B (zh) * 2017-12-12 2021-09-10 武汉波睿达生物科技有限公司 重组pg9-car分子的构建及其在清除hiv-1感染细胞中的应用
CN108070033A (zh) * 2017-12-12 2018-05-25 武汉波睿达生物科技有限公司 一种3bnc-car分子的构建及其在杀灭hiv-1感染细胞中的应用
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
CN111253493B (zh) * 2020-03-05 2021-03-23 武汉科技大学 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用
CN111249308A (zh) * 2020-03-18 2020-06-09 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Car-t技术在预防和治疗冠状病毒感染性疾病中的应用
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技(上海)有限公司 用于病原体清除的嵌合抗原受体及其应用
CN113943709A (zh) * 2021-09-14 2022-01-18 复旦大学 一种多功能抗hiv-1的car-t细胞及其构建方法和应用
CN116333166B (zh) * 2023-02-08 2023-10-03 珠海臻谱基因科技有限公司 一种靶向HIV gp120蛋白的重组干扰素及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101280016A (zh) * 2008-05-27 2008-10-08 中国人民解放军第二军医大学 可卡因-苯丙胺调节转录肽单链抗体及其应用
CN105980402A (zh) * 2013-12-20 2016-09-28 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019759A1 (en) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
EP3074419B1 (en) * 2013-11-25 2018-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
SI3271389T1 (sl) * 2015-03-20 2020-09-30 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nevtralizirajoča protitelesa proti GP120 in njihova uporaba
CN106279432B (zh) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 一种vc-car分子及在清除hiv-1感染细胞中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101280016A (zh) * 2008-05-27 2008-10-08 中国人民解放军第二军医大学 可卡因-苯丙胺调节转录肽单链抗体及其应用
CN105980402A (zh) * 2013-12-20 2016-09-28 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANS59202.1;Ellebrecht,C.T.;《GENBANK》;20160719;全文 *
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cell sand Increased Antileukemic Efficacy In Vivo;Michael C. Milone等;《Molecular Therapy》;20090831;第17卷(第08期);第1453-1464页 *
Identification of a CD4-Bingding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth;Huang J等;《Immunity》;20161115;第45卷(第5期);第1108-1121页 *
新型抗HER2嵌合性抗原受体的构建及其体外、体内功能的评价;孙美丽;《中国博士学位论文全文数据库,医药卫生科技辑》;20150415(第04期);第15页第二节 实验方法部分 *

Also Published As

Publication number Publication date
EP3511347A1 (en) 2019-07-17
CN107098969A (zh) 2017-08-29
JP2020513782A (ja) 2020-05-21
US20190389940A1 (en) 2019-12-26
EP3511347A4 (en) 2019-10-16
JP6890664B2 (ja) 2021-06-18
WO2019000620A1 (zh) 2019-01-03

Similar Documents

Publication Publication Date Title
CN107098969B (zh) 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
KR102630017B1 (ko) 프로그램화된 사멸 1 리간드 1 (pd-l1) 결합 단백질 및 그의 사용 방법
US6287571B1 (en) Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
CN110747198B (zh) 毕赤酵母生产重组人源ⅱ型胶原蛋白单链的方法
CN110022906A (zh) 抗bcma car t细胞组合物
CN112458058B (zh) 一种过表达traf6的dc细胞、dc细胞疫苗及构建方法和应用
CN110656090B (zh) 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
US8128922B2 (en) Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
CN111089972B (zh) 一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
CN107988258B (zh) 一种基于黑猩猩腺病毒载体的寨卡病毒疫苗及其制备方法
CN108059675B (zh) 重组pg9-car分子的构建及其在清除hiv-1感染细胞中的应用
WO1996039178A1 (en) A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
CN108070033A (zh) 一种3bnc-car分子的构建及其在杀灭hiv-1感染细胞中的应用
CN107002041B (zh) 在分泌弗林蛋白酶的哺乳动物表达系统中产生被完全加工且功能性的因子x
CN111272998A (zh) 一种同时检测中枢脱髓鞘自身抗体aqp4、mog和mbp的方法
CN111214496B (zh) 一种重组溶瘤病毒在制备治疗淋巴瘤药物组合物中的用途
CN109097392A (zh) 一种基于PiggyBac载体的Her2-CAR-T系统构建方法
CN108660111B (zh) Car-cik转基因细胞及其制备方法和应用
CN112522205B (zh) 一种过表达血管紧张素转换酶2的细胞系及其制备方法与应用
CN113355295A (zh) 一种表达人gm-csf的重组溶瘤新城疫病毒及其应用
AU685399B2 (en) Improvements in or relating to immune response modification
CN109957551B (zh) 表达人β-防御素2的重组痘苗病毒及其应用
CN114107384A (zh) 一种靶向人非小细胞肺癌细胞株中eml4-alk融合基因变体1的载体及应用
KR20190017363A (ko) 바이오틴을 이용한 단백질의 상호작용체를 확인하는 방법
US20040072781A1 (en) Materials and methods relating to fusion proteins an immune response

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Zhang Tongcun

Inventor after: Gu Chaojiang

Inventor before: Zhang Tongcun

Inventor before: Hu Guang

Inventor before: Gu Chaojiang

Inventor before: Zhang Shangkun

Inventor before: Huang Zheng

Inventor before: Tang Jie

Inventor before: Tang Liu

CB03 Change of inventor or designer information
TA01 Transfer of patent application right

Effective date of registration: 20180829

Address after: 430000 Wuhan Donghu Development Zone High-tech Avenue 666 Wuhan National Biological Industry Base Project B, C, D Development Building B1

Applicant after: Wuhan Ruida Biotechnology Co. Ltd.

Address before: 430000 No. 40 of No. 1 Accelerator Workshop of Guanggu International Biomedical Enterprise, No. 388 High-tech Second Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province

Applicant before: Wuhan Valley bio Pharmaceutical Technology Co.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant